ArticleNeurogastroenterology and motility2019
Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome.
Article in Neurogastroenterology and motility, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.Clinical and translational gastroenterology · 2020Trial
- A Dance and Yoga Intervention for Girls with Functional Abdominal Pain: Effects on Pain Frequency, Depressive Symptoms, Quality of Life, School Absenteeism, and Somatic Symptoms: A Randomized Controlled Trial.Children (Basel, Switzerland) · 2026Article
- Initiating multi-strain probiotics is associated with clinically meaningful symptom relief, better quality of life, and fewer treatment escalations in IBS-D/IBS-M: a Chinese real-world propensity-matched cohort study.Frontiers in medicine · 2026Article
- Treatment of Irritable Bowel Syndrome With Antispasmolytics in Taiwan, Hong Kong, and Vietnam: A Delphi Expert Consensus Statement.Journal of neurogastroenterology and motility · 2025Article
- Quality assessment of irritable bowel syndrome-related medical information on major video platforms in China: a cross-sectional study.BMJ open · 2025Article
- The Impact and Interactions of Race and Gender on Healthcare Use and Spending in Irritable Bowel Syndrome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- Effects ofNutrients · 2024Article
- Co-Morbidities of Irritable Bowel Syndrome in a Racially and Ethnically Diverse Population.Journal of clinical medicine · 2024Article
- Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study.Journal of neurogastroenterology and motility · 2024Article
- Letter to the Editor: Survey-Based Analysis of Clinical Treatment Status of Irritable Bowel Syndrome in Korea: Suggestions for Future Research.Journal of Korean medical science · 2023Article
- Irritable bowel syndrome and mental health comorbidity - approach to multidisciplinary management.Nature reviews. Gastroenterology & hepatology · 2023Review
- Long-Term Follow-up of Individual Therapist Delivered and Standardized Hypnotherapy Recordings in Pediatric Irritable Bowel Syndrome or Functional Abdominal Pain.Journal of pediatric gastroenterology and nutrition · 2022Article
- The impact of vestibular schwannoma and its management on employment.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Article
- The relationships between IBS and perceptions of physical and mental health-a Norwegian twin study.BMC gastroenterology · 2022Article
- Effect ofWorld journal of gastroenterology · 2022Observational
- Examining the optimal cutoff values of HADS, PHQ-9 and GAD-7 as screening instruments for depression and anxiety in irritable bowel syndrome.Neurogastroenterology and motility · 2021Article
- Perceived Barriers to Treatment in Persons Treated for Functional Gastrointestinal Disease with Constipation.Digestive diseases and sciences · 2021Article
- Age-Related Decrease in Abdominal Pain and Associated Structural- and Functional Mechanisms: An Exploratory Study in Healthy Individuals and Irritable Bowel Syndrome Patients.Frontiers in pharmacology · 2021Article
- Probiotics in irritable bowel syndrome - is the quest for the right strain over? Rapid review of existing guidelines and recommendations.Przeglad gastroenterologiczny · 2021Review
- Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis.Gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) is a brain-gut disorder, of which the natural course varies between patients and is difficult to predict. This study aimed to evaluate symptom evolution over a 5-year follow-up period and to identify baseline predictors for symptom severity and quality of life (QoL) at follow-up.
methodsMaastricht IBS cohort participants completed questionnaires upon inclusion regarding demographics and lifestyle, gastrointestinal (GI) symptoms, anxiety and depression, and QoL. The same questionnaires, in addition to others, were completed after 5 years. Rome criteria were confirmed face-to-face at initial enrollment and through telephonic interviews at follow-up. KEY
resultsAt a mean follow-up of 4.7 years, 379 patients were approached of whom 203 (53.7%) responded. Of these, 161 were reached by telephone and analyzed; 49 (30.4%) did not fulfill the Rome III criteria at follow-up and had lower levels of GI symptoms and GI-specific anxiety compared to those remaining Rome III-positive (P < 0.001). However, Rome III-negative patients had comparable levels of QoL and life satisfaction, comorbid anxiety and depression, work absenteeism, and impaired productivity. No baseline predictors were found for being Rome III-positive or Rome III-negative. However, greater age and lower baseline physical QoL predicted lower physical QoL at follow-up (P < 0.005 and P < 0.01, respectively), while lower baseline mental QoL predicted lower mental QoL at follow-up (P = 0.005). Additionally, higher anxiety and depression scores at follow-up were associated with lower QoL and life satisfaction at follow-up (P < 0.001). CONCLUSIONS AND INFERENCES: Long-term QoL and general well-being might depend on concurrent psychological symptoms, rather than GI symptom improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.